Core Viewpoint - The announcement highlights a strategic partnership between Nona Bio and Umoja Biopharma to advance the development of in vivo CAR-T cell products through the integration of their respective platforms [1][2]. Group 1: Partnership Details - Nona Bio has entered into an evaluation and licensing agreement with Umoja Biopharma to combine their HCAb Harbour Mice platform and NonaCarFxTM platform with Umoja's VivoVecTM platform [1]. - The agreement signifies an expansion of the strategic partnership established in September 2024 [1]. - Nona Bio will receive an upfront payment, potential option payments, and milestone payments related to the discovery and development of collaborative projects [1]. Group 2: Company Profiles - Umoja Biopharma is a clinical-stage biotechnology company focused on developing accessible and effective in vivo CAR-T cell therapies for oncology and autoimmune diseases [2]. - The VivoVecTM gene delivery technology enhances the patient's immune system's ability to combat diseases [2]. - Umoja Biopharma operates an advanced lentiviral vector development and manufacturing facility located in Louisville, Colorado, which supports its core technology [2].

Core Insights - Heptares Therapeutics has entered into an evaluation and licensing agreement with Umoja Biopharma to combine their respective platforms for the development of in vivo CAR-T cell products, marking a deepening of their strategic partnership established in September 2024 [1][2] Company Overview - Umoja Biopharma is a clinical-stage biotechnology company focused on developing more accessible and effective in vivo CAR-T cell therapies for oncology and autoimmune diseases [2] - The company's VivoVec gene delivery technology enhances the patient's immune system's ability to combat diseases, supported by an advanced manufacturing facility located in Louisville, Colorado [2] - Umoja Biopharma aims to improve the accessibility and effectiveness of immunotherapies, helping more patients lead better and fuller lives [2]

根据协议条款，诺纳生物将有权获得首付款、潜在选择权付款，以及合作项目发现及开发相关里程碑付 款。Umoja Biopharma将负责所有后续产品的开发和商业化工作。 Umoja Biopharma, Inc.是一家处于临床阶段的生物技术公司，致力于在肿瘤和自身免疫性疾病领域开发 更具可及性和有效性的体内CAR-T细胞疗法。Umoja Biopharma的VivoVec体内基因递送技术可增强患者 自身免疫系统对抗疾病的能力。支持其核心技术的是该公司位于美国科罗拉多州路易斯维尔的先进慢病 毒载体开发和制造工厂。Umoja Biopharma相信，其科学研究可以提高免疫疗法的可及性和有效性，帮 助更多患者享有更美好、更充实的生活。 智通财经APP讯，和铂医药-B(02142)发布公告，本公司全资子公司诺纳生物(苏州)有限公司(诺纳生物) 已与Umoja Biopharma, Inc.(Umoja Biopharma)订立评估与授权协议(协议)，旨在将诺纳生物的HCAb Harbour Mice平台和NonaCarFx平台与Umoja Biopharma的VivoVec平台相结合，共同推进多款体内CAR- T细胞产品 ...